siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection.
Raghu Chandrashekhar HariharapuraVenkata Rao JosyulaRaghu Chandrashekar HariharapuraPublished in: Virusdisease (2019)
The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.
Keyphrases
- herpes simplex virus
- cancer therapy
- randomized controlled trial
- end stage renal disease
- ejection fraction
- copy number
- small molecule
- newly diagnosed
- chronic kidney disease
- hyaluronic acid
- genome wide
- drug delivery
- sars cov
- prognostic factors
- drug induced
- patient reported outcomes
- emergency department
- high glucose
- gene expression
- oxidative stress
- adverse drug
- genome wide analysis